PARP inhibitors in ovarian cancer

被引：162

作者：

Franzese, Elisena ^{[1
]}

Centonze, Sara ^{[1
]}

Diana, Anna ^{[1
]}

Carlino, Francesca ^{[1
]}

Guerrera, Luigi Pio ^{[1
]}

Di Napoli, Marilena ^{[2
]}

De Vita, Ferdinando ^{[1
]}

Pignata, Sandro ^{[2
]}

Ciardiello, Fortunato ^{[1
]}

Orditura, Michele ^{[1
]}

机构：

[1] Luigi Vanvitelli Univ Campania, Sch Med, Dept Precis Med, Div Med Oncol, I-80131 Naples, Italy

[2] IRCCS, Ist Nazl Studio Cura Tumori Fdn G Pascale, I-80131 Naples, Italy

来源：

CANCER TREATMENT REVIEWS | 2019年 / 73卷

关键词：

Ovarian cancer; PARP inhibitors; Olaparib; Niraparib; Rucaparib; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; MAINTENANCE THERAPY; DOUBLE-BLIND; OPEN-LABEL; MUTATION CARRIERS; BRCA2; MUTATIONS; PHASE-I; OLAPARIB; CARCINOMA;

D O I：

10.1016/j.ctrv.2018.12.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. In this review, we provide an updated overview of the available results of recent clinical trials on the three Food and Drug Administration and European Medicines Agency approved PARPis in ovarian cancer: olaparib, niraparib, and rucaparib. Furthermore, we anticipate the future perspective of combination regimens with antiangiogenic, immunocheckpoint inhibitors, and other biological agents as strategies to overcome resistance mechanisms, potentiate the therapeutic efficacy, and expand their clinical use in non-HR deficient tumors.

引用

页码：1 / 9

页数：9

共 67 条

[1] Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer. [J].

Adams, Sarah Foster ;

Rixe, Olivier ;

Lee, Ji-Hyun ;

McCance, Dennis J. ;

Westgate, Sheri ;

Eberhardt, Steven C. ;

Rutledge, Teresa ;

Muller, Carolyn .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[2]

[Anonymous], ANN ONCOL

[3]

[Anonymous], ANN ONCOL S8

[4]

[Anonymous], J CLIN ONCOL S

[5]

[Anonymous], 2018, ANN ONCOL, DOI DOI 10.1093/ANNONC/MDY285.145

[6] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].

Antoniou, A ;

Pharoah, PDP ;

Narod, S ;

Risch, HA ;

Eyfjord, JE ;

Hopper, JL ;

Loman, N ;

Olsson, H ;

Johannsson, O ;

Borg, Å ;

Pasini, B ;

Radice, P ;

Manoukian, S ;

Eccles, DM ;

Tang, N ;

Olah, E ;

Anton-Culver, H ;

Warner, E ;

Lubinski, J ;

Gronwald, J ;

Gorski, B ;

Tulinius, H ;

Thorlacius, S ;

Eerola, H ;

Nevanlinna, H ;

Syrjäkoski, K ;

Kallioniemi, OP ;

Thompson, D ;

Evans, C ;

Peto, J ;

Lalloo, F ;

Evans, DG ;

Easton, DF .

AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130

[7] Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases [J].

Ba, Xueqing ;

Garg, Nisha Jain .

AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (03) :946-955

[8] STING: infection, inflammation and cancer [J].

Barber, Glen N. .

NATURE REVIEWS IMMUNOLOGY, 2015, 15 (12) :760-770

[9] Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation [J].

Barkauskaite, Eva ;

Jankevicius, Gytis ;

Ahel, Ivan .

MOLECULAR CELL, 2015, 58 (06) :935-946

[10] Safety and dose modification for patients receiving niraparib [J].

Berek, J. S. ;

Matulonis, U. A. ;

Peen, U. ;

Ghatage, P. ;

Mahner, S. ;

Redondo, A. ;

Lesoin, A. ;

Colombo, N. ;

Vergote, I. ;

Rosengarten, O. ;

Ledermann, J. ;

Pineda, M. ;

Ellard, S. ;

Sehouli, J. ;

Gonzalez-Martin, A. ;

Berton-Rigaud, D. ;

Madry, R. ;

Reinthaller, A. ;

Hazard, S. ;

Guo, W. ;

Mirza, M. R. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1784-1792

← 1 2 3 4 5 6 7 →